[go: up one dir, main page]

ES2164967T3 - Derivados de 4-hidroxi-piperidina. - Google Patents

Derivados de 4-hidroxi-piperidina.

Info

Publication number
ES2164967T3
ES2164967T3 ES97111742T ES97111742T ES2164967T3 ES 2164967 T3 ES2164967 T3 ES 2164967T3 ES 97111742 T ES97111742 T ES 97111742T ES 97111742 T ES97111742 T ES 97111742T ES 2164967 T3 ES2164967 T3 ES 2164967T3
Authority
ES
Spain
Prior art keywords
sup
hydroxy
hydrogen
rent
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97111742T
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Buttelmann
Neidhart Marie-Paule Heitz
Emmanuel Pinard
Rene Wyler
Stephan Roever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2164967T3 publication Critical patent/ES2164967T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL EN LA QUE X ES SUB,2} -; R SUP,1} TRO HIDROGENO, HALOGENO, HIDROXI, AMINO, NITRO, ALQUIL IOR SULFONILAMIDO, 1 ILO) O ACETAMIDO; R SUP,5}, R SUP,6} SON, INDEPENDIENTEMENTE UNO DE OTRO, HIDROGENO, ALQUILO INFERIOR, HIDROXI, ALCOXI INFERIOR O OXO; R SUP,7} OTRO, HIDROGENO, ALQUILO INFERIOR, HALOGENO, TRIFLUOROMETILO O ALCOXI INFERIOR; N ES 0 O 1; Y A SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. LOS COMPUESTOS DE LA PRESENTE INVENCION SON BLOQUEADORES SELECTIVOS DEL SUBTIPO DE RECEPTORES NMDA (N - METIL - D ASPARTATO).
ES97111742T 1996-07-19 1997-07-10 Derivados de 4-hidroxi-piperidina. Expired - Lifetime ES2164967T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111660 1996-07-19
EP97105366 1997-04-01

Publications (1)

Publication Number Publication Date
ES2164967T3 true ES2164967T3 (es) 2002-03-01

Family

ID=26142078

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97111742T Expired - Lifetime ES2164967T3 (es) 1996-07-19 1997-07-10 Derivados de 4-hidroxi-piperidina.

Country Status (33)

Country Link
US (1) US5889026A (es)
EP (1) EP0824098B1 (es)
JP (1) JP3179050B2 (es)
KR (1) KR100235804B1 (es)
CN (1) CN1120154C (es)
AR (2) AR007898A1 (es)
AT (1) ATE207899T1 (es)
AU (1) AU719352B2 (es)
BR (1) BR9704031A (es)
CA (1) CA2210044C (es)
CO (1) CO4900064A1 (es)
CZ (1) CZ290898B6 (es)
DE (1) DE69707782T2 (es)
DK (1) DK0824098T3 (es)
ES (1) ES2164967T3 (es)
HR (1) HRP970394A2 (es)
HU (1) HUP9701194A3 (es)
ID (1) ID19632A (es)
IL (1) IL121299A (es)
MA (1) MA24274A1 (es)
MX (1) MX9705387A (es)
NO (1) NO308657B1 (es)
NZ (1) NZ328330A (es)
PE (1) PE86398A1 (es)
PL (1) PL321201A1 (es)
PT (1) PT824098E (es)
RU (1) RU2178412C2 (es)
SG (1) SG60085A1 (es)
TR (1) TR199700659A2 (es)
TW (1) TW498067B (es)
UY (1) UY24625A1 (es)
YU (1) YU30197A (es)
ZA (1) ZA976224B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
JP4611524B2 (ja) * 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
EP1131290B1 (en) 1998-11-20 2008-02-20 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US6407235B1 (en) * 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
SI1409477T1 (sl) * 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
ATE446298T1 (de) * 2001-11-30 2009-11-15 Osi Pharm Inc Verbindungen, die für adenosin a1 und a3 rezeptoren spezifisch sind, und deren anwendungen
AU2002366811B2 (en) 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
US6951884B2 (en) * 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
EP1666464A4 (en) * 2003-09-25 2008-12-10 Shionogi & Co PIPERIDINE DERIVATIVE HAVING ANTAGONIST ACTIVITY OF THE NDMA RECEPTOR
DE602004017206D1 (de) * 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
HUP0401522A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
MX2009014216A (es) * 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
US7869022B2 (en) 2007-07-18 2011-01-11 Asml Netherlands B.V. Inspection method and apparatus lithographic apparatus, lithographic processing cell, device manufacturing method and distance measuring system
CA2722776A1 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
US7874106B2 (en) * 2009-02-13 2011-01-25 Ykk Corporation Of America Sill flashing and end dam assembly
KR101769396B1 (ko) * 2009-10-19 2017-08-18 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
MX337933B (es) * 2009-10-19 2016-03-29 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU61061A1 (ru) * 1940-11-27 1941-11-30 И.И. Петров Прибор дл увлажнени и дезодорации воздуха
US3850935A (en) * 1971-10-16 1974-11-26 Sumitomo Chemical Co Process for producing piperidine derivatives by degrading quaternary piperidinium salts
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
TW281670B (es) * 1993-09-02 1996-07-21 Hoffmann La Roche
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists

Also Published As

Publication number Publication date
CN1171396A (zh) 1998-01-28
KR980009244A (ko) 1998-04-30
DK0824098T3 (da) 2002-02-18
HU9701194D0 (en) 1997-09-29
US5889026A (en) 1999-03-30
NO973337D0 (no) 1997-07-18
IL121299A (en) 2001-12-23
JP3179050B2 (ja) 2001-06-25
ZA976224B (en) 1998-01-19
CA2210044A1 (en) 1998-01-19
BR9704031A (pt) 1998-12-29
SG60085A1 (en) 1999-02-22
AR007897A1 (es) 1999-11-24
HRP970394A2 (en) 1998-06-30
DE69707782T2 (de) 2002-06-20
AR007898A1 (es) 1999-11-24
TR199700659A2 (xx) 1998-02-21
AU719352B2 (en) 2000-05-04
NO973337L (no) 1998-01-20
IL121299A0 (en) 1998-01-04
NZ328330A (en) 1998-05-27
ID19632A (id) 1998-07-23
HK1009124A1 (en) 1999-05-28
RU2178412C2 (ru) 2002-01-20
NO308657B1 (no) 2000-10-09
PE86398A1 (es) 1998-12-10
CZ227497A3 (cs) 1998-02-18
AU2875697A (en) 1998-01-29
CO4900064A1 (es) 2000-03-27
EP0824098A1 (en) 1998-02-18
ATE207899T1 (de) 2001-11-15
YU30197A (sh) 1999-12-27
UY24625A1 (es) 2000-12-29
HUP9701194A2 (hu) 1999-05-28
DE69707782D1 (de) 2001-12-06
EP0824098B1 (en) 2001-10-31
KR100235804B1 (ko) 1999-12-15
MA24274A1 (fr) 1998-04-01
TW498067B (en) 2002-08-11
PT824098E (pt) 2002-04-29
CZ290898B6 (cs) 2002-11-13
JPH1067742A (ja) 1998-03-10
MX9705387A (es) 1998-01-31
CN1120154C (zh) 2003-09-03
PL321201A1 (en) 1998-02-02
HUP9701194A3 (en) 1999-06-28
CA2210044C (en) 2006-02-14

Similar Documents

Publication Publication Date Title
ES2164967T3 (es) Derivados de 4-hidroxi-piperidina.
ES2165357T3 (es) Derivados de metileno-oxiindol y procedimiento de elaboracion.
ES2084914T3 (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su preparacion.
TW347387B (en) Piperidine derivatives
ES2065133T3 (es) Derivados de piperazina.
DK104792A (da) 8-chlor-1,5-benzothiazepinderivater og fremgangsmaade til fremstilling deraf
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
AR005229A1 (es) Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende.
ES2177767T3 (es) Analogos de suksdorfina, composiciones de los mismos y metodos para elaborar y usar los mismos.
ES2160106T3 (es) Derivados de la quinazolina.
DK0587499T3 (da) Benzopyranforbindelser, fremgangsmåde til deres fremstilling og deres anvendelse som cellebeskyttelsesmidler
YU52000A (sh) Jedinjenja meta-azaciklične amino benzojeve kiseline i njihovi derivati, koji su antagonisti integrina
EP0231139A3 (en) Dihydrobenzofurane and chromane carboxamide derivatives, processes for their preparation and their use as neuroleptics
ES2046110A1 (es) Procedimiento de preparacion de nuevos compuestos derivados de bencimidazol.
ES2123873T3 (es) Pirrolocarbazol.
KR850005843A (ko) 치환된 헥사히드로 아릴퀴놀리진의 제조방법
NO940006L (no) Aminosyrederivater
DK0482084T3 (da) (1,2N)- og (3,2N)-carbocyklisk-2-amino-tetralin-derivater.
ES2103590T3 (es) Derivados del acido 3-(indol-3-il) propenoico utilizables como antagonistas nmda.
EP0802179A4 (en) DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER
DK0725776T3 (da) 3-Aryl-4-alkyl- og 4,5-dialkyl-4H-1,2,4-triazoler anvendelige som hukommelsesforbedrende midler
ATE79625T1 (de) Substituierte 1,3,4,9-tetrahydropyrano(3,4b>indol-1-essigs|uren.
ES2165022T3 (es) Derivados de acido piridonacarboxilico y sus intermedios de sintesis.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 824098

Country of ref document: ES